DUBLIN, Ireland, Dec. 20, 2018 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced…Original Article
You may also like
Orexo Submits New Drug Application to FDA for OX124, a...
FDA Accepts Defender Pharmaceuticals’ New Drug...
Abeona Therapeutics Submits Biologics License...
Basilea Announces FDA Acceptance of New Drug...
Alpha Cognition Announces Submission of New Drug...
FDA Issues Complete Response Letter for PDP-716 NDA...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.